Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Thoracic Oncology

• Publication date

  2017-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jtho.2017.04.003PMID 28428148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

  2017influential reference
• Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

  2016cited by this paper
• Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer

  2016cited by this paper
• Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.

  2016cited by this paper
• Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

  2016influential reference
• Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

  2016cited by this paper
• Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

  2016cited by this paper
• The current and future state of companion diagnostics

  2015cited by this paper
• The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC).

  2015cited by this paper
• First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

  2015cited by this paper
• EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

  2015cited by this paper
• Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer.

  2015cited by this paper
• Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

  2015cited by this paper
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  2014cited by this paper
• Liquid biopsies: genotyping circulating tumor DNA.

  2014cited by this paper
• Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis

  2014cited by this paper
• Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

  2014cited by this paper
• Gefitinib Treatment in EGFR Mutated Caucasian NSCLC

  2014cited by this paper
• Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

  2014cited by this paper
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  2013cited by this paper
• Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutations

  2013cited by this paper
• Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Cell-free nucleic acids as biomarkers in cancer patients

  2011cited by this paper
• Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

  2010cited by this paper
• Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009

  2010cited by this paper
• Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

  2009cited by this paper
• Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper

• Integrating liquid biopsies in non-small cell lung cancer diagnosis and management: opportunities and challenges.

  2026cites this paper
• An allele-specific quantitative PCR strategy for detection of EGFR T790M mutations by liquid biopsy in non-small cell lung cancer patients.

  2025cites this paper
• MRD4U: A path to development for personalized liquid biopsy for children with central nervous system tumors

  2025cites this paper
• Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy.

  2025cites this paper
• Circulating tumor DNA in lung cancer: a bibliometric analysis of studies published from 2001 to 2024

  2025cites this paper
• Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma

  2025cites this paper
• Comparison of tissue-based and plasma-based testing for EGFR mutation in non–small cell lung cancer patients

  2025cites this paper
• Artificial Intelligence-Enhanced Liquid Biopsy and Radiomics in Early-Stage Lung Cancer Detection: A Precision Oncology Paradigm

  2025cites this paper
• Digital PCR: from early developments to its future application in clinics

  2025cites this paper
• Third‐Generation EGFR‐TKIs in T790M‐Negative NSCLC After First/Second‐Generation EGFR‐TKI Failure: A Retrospective Study

  2025cites this paper
• Prognostic determinants and functional role of PIK3C2G in stage IIb-IIIa lung adenocarcinoma: insights from clinical and molecular analyses

  2025cites this paper
• A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis.

  2024cites this paper
• Detection of EGFR T790M mutation using liquid biopsy for non-small cell lung cancer: Utility of droplet digital polymerase chain reaction vs. cobas real-time polymerase chain reaction.

  2024cites this paper
• Cancer Biomarkers - Emerging Trends and Clinical Implications for personalized treatment

  2024cites this paper
• Liquid biopsy for the management of NSCLC patients under osimertinib treatment

  2024cites this paper
• Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer.

  2024cites this paper
• Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors

  2024cites this paper
• Application of liquid biopsy in lung cancer management.

  2024cites this paper
• A dual-functional microfluidic chip for guiding personalized lung cancer medicine: combining EGFR mutation detection and organoid-based drug response test.

  2024cites this paper
• Values of circulating tumor DNA for non-small cell lung cancer patients receiving neoadjuvant therapy, progress and challenges: a narrative review

  2023cites this paper
• Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China

  2023cites this paper
• Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer

  2023cites this paper
• Cost-Effectiveness Analysis of Three Diagnostic Strategies for the Detection of EGFR Mutation in Advanced Non-Small Cell Lung Cancer

  2023cites this paper
• Somatic mutation detection and KRAS amplification in testicular germ cell tumors

  2023cites this paper
• Rapid determination of the presence of EGFR mutations with DNA-based nanocalipers.

  2023cites this paper
• Osimertinib as first-line treatment for recurrent lung cancer patients with EGFR mutation

  2023cites this paper
• Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study

  2023cites this paper
• EGFR-Directed Therapy in Lung Cancer

  2023cites this paper
• Enrichment of Circulating Tumor Cells of Lung Cancer and Correlation With Serum Leukomonocyte and Tumor Biomarkers: A Retrospective Study

  2023cites this paper
• Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer.

  2023cites this paper
• Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects.

  2023cites this paper
• Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study.

  2023cites this paper
• Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation

  2023cites this paper
• Liquid biopsy—ready to guide treatment decisions?

  2023cites this paper
• Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients

  2023cites this paper
• Liquid biopsy for early detection of lung cancer

  2023influential citation
• „Liquid biopsy“ – schon reif für Therapieentscheidungen?

  2023cites this paper
• Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.

  2023cites this paper
• Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies

  2023cites this paper
• Improving non-small-cell lung cancer survival through molecular characterization: Perspective of a multidisciplinary expert panel.

  2023cites this paper
• Real‐world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non‐small cell lung cancer

  2023cites this paper
• BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: a case report and review of the literature.

  2023cites this paper
• An intravenous DNA-binding priming agent protects cell-free DNA and improves the sensitivity of liquid biopsies

  2023cites this paper
• Network approach in liquidomics landscape

  2023cites this paper
• Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naïve Stage IV Non-Small Cell Lung Cancer Patients

  2022cites this paper
• A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation

  2022cites this paper
• Detection of non-metastatic non-small-cell lung cancer in urine by methylation-specific PCR analysis: A feasibility study.

  2022cites this paper
• Characteristics of EGFR Mutations in Plasma Samples in Non-Small Cell Lung Cancer Patients after Treatment with 1st and 2nd Generation of TKI at Bach Mai Hospital

  2022cites this paper
• Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC

  2022cites this paper
• Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer.

  2022cites this paper
• Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma

  2022cites this paper
• Detection of EGFR gene with a droplet digital PCR chip integrating a double-layer glass reservoir.

  2022cites this paper
• Sputum cell‐free DNA for detection of alterations of multiple driver genes in lung adenocarcinoma

  2022cites this paper
• Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.

  2022cites this paper
• Status of liquid profiling in precision oncology – the need for integrative diagnostics for successful implementation into standard care

  2022cites this paper
• Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer

  2022cites this paper
• Molecular biomarkers and liquid biopsies in lung cancer.

  2022cites this paper
• EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits

  2022cites this paper
• Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges

  2022cites this paper
• Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer

  2022cites this paper
• Liquid Profiling for Cancer Patient Stratification in Precision Medicine—Current Status and Challenges for Successful Implementation in Standard Care

  2022influential citation
• The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.

  2022cites this paper
• Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?

  2022cites this paper
• Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)

  2022cites this paper
• The efficacy of T790M mutation testing in liquid biopsy—Real clinic data

  2022influential citation
• Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid

  2022cites this paper
• El cáncer de pulmón de células no pequeñas en la era de la medicina de precisión

  2022cites this paper
• Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib

  2021cites this paper
• The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy

  2021influential citation
• Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients.

  2021cites this paper
• Late phase 1 studies: concepts and outcomes.

  2021cites this paper
• A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients

  2021cites this paper
• Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer

  2021cites this paper
• Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy

  2021cites this paper
• CMAR_A_329900 6901..6910

  2021cites this paper
• Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations

  2021cites this paper
• Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

  2021cites this paper
• Photonic crystal barcode: An emerging tool for cancer diagnosis

  2021cites this paper
• A phase II study of osimertinib for radiotherapy-naïve CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L).

  2021cites this paper
• Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers

  2021cites this paper
• How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review.

  2021cites this paper
• Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

  2021cites this paper
• Lung Cancer Stem Cells—Origin, Diagnostic Techniques and Perspective for Therapies

  2021cites this paper
• Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma

  2021cites this paper
• Endonuclease IV-Regulated DNAzyme Motor for Universal Single-nucleotide Variation Discrimination.

  2021cites this paper
• Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.

  2021cites this paper
• Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

  2021cites this paper
• Detection of Circulating Tumor DNA in Patients with Thyroid Nodules

  2021cites this paper
• Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System

  2021cites this paper
• The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer

  2021cites this paper
• Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs

  2021cites this paper
• Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer

  2021cites this paper
• Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC

  2021cites this paper
• Circulating Biomarkers for Early Stage Non-Small Cell Lung Carcinoma Detection: Supplementation to Low‐Dose Computed Tomography

  2021cites this paper
• Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs

  2021cites this paper
• Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR

  2021cites this paper
• Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective.

  2021cites this paper
• Bronchial Washing Fluid Versus Plasma and Bronchoscopy Biopsy Samples for Detecting Epidermal Growth Factor Receptor Mutation Status in Lung Cancer

  2021cites this paper
• The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management

  2021cites this paper
• Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.

  2021cites this paper